Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 6Terminated 2Recruiting 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 109Cyclophosphamide 85fludarabine 67Carboplatin 59Injections 58Bevacizumab 52Specimen Handling 42Gemcitabine 41Paclitaxel 40Magnetic Resonance Spectroscopy 40venetoclax 38Nivolumab 38Cisplatin 37Dexamethasone 35Biopsy 34Temozolomide 31Docetaxel 29atezolizumab 27Oxaliplatin 26Capecitabine 26Pemetrexed 25Fluorouracil 25toripalimab 24abemaciclib 24Irinotecan 24Azacitidine 24Fulvestrant 23Rituximab 21fludarabine phosphate 20durvalumab 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recruiting × entinostat × Clear all
NCT05053971 2026-04-13

Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1/2 Recruiting
49 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03838042 2024-02-07

INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

University Hospital Heidelberg

Phase 1/2 Recruiting
91 enrolled
CNS

Central Nervous System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡